Gefitinib vs Pembrolizumab

Gefitinib vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Gefitinib and Pembrolizumab.

Mechanism of Action

Gefitinib: Selective reversible inhibitor of EGFR tyrosine kinase.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Gefitinib — 48 hours; Pembrolizumab — 26 days.

Chemical Properties

Molecular Formula: Gefitinib — C22H24ClFN4O3.

Molecular Weight: Gefitinib — 446.9000 g/mol.

Type: Gefitinib — Small molecule; Pembrolizumab — Antibody.